| Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA. 4-5) bivalent vaccines against hospitalisation in England FCM Kirsebom, N Andrews, J Stowe, G Dabrera, M Ramsay, JL Bernal EClinicalMedicine 71, 2024 | 1 | 2024 |
| Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK SN Ladhani, PJ White, H Campbell, S Mandal, R Borrow, N Andrews, ... The Lancet Infectious Diseases, 2024 | 2 | 2024 |
| Effects of BNT162b2 Messenger RNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Deaths From COVID-19 in Adults Aged≥ 70 Years JL Bernal, N Andrews, C Gower, J Stowe, E Tessier, R Simmons, ... Clinical infectious diseases: an official publication of the Infectious …, 2024 | | 2024 |
| Effects of BNT162b2 Messenger RNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Deaths From COVID-19 in Adults Aged≥ 70 Years J Lopez Bernal, N Andrews, C Gower, J Stowe, E Tessier, R Simmons, ... Clinical Infectious Diseases 78 (2), 349-351, 2024 | | 2024 |
| Invasive pneumococcal disease 3 years after introduction of a reduced 1+ 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective … M Bertran, JC D'Aeth, F Abdullahi, S Eletu, NJ Andrews, ME Ramsay, ... The Lancet Infectious Diseases, 2024 | 8 | 2024 |
| Post-peak mpox in England: epidemiology, reinfection, and vaccine effectiveness. Data from 2023 H Charles, K Thorley, C Turner, KF Bennet, N Andrews, M Bertran, ... medRxiv, 2024.02. 26.24303362, 2024 | | 2024 |
| Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort PD Kirwan, VJ Hall, S Foulkes, AD Otter, K Munro, D Sparkes, A Howells, ... The Lancet Regional Health–Europe 36, 2024 | 4 | 2024 |
| Transmission dynamics and effect of control measures on the 2022 outbreak of mpox among gay, bisexual, and other men who have sex with men in England: a mathematical modelling … XS Zhang, S Mandal, H Mohammed, C Turner, I Florence, J Walker, ... The Lancet Infectious Diseases 24 (1), 65-74, 2024 | 21 | 2024 |
| The impact of vaccination and SARS-CoV-2 variants on the virological response to SARS-CoV-2 infections during the Alpha, Delta, and Omicron waves in England R Lunt, C Quinot, F Kirsebom, N Andrews, C Skarnes, L Letley, D Haskins, ... Journal of Infection 88 (1), 21-29, 2024 | 2 | 2024 |
| Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents H Ratcliffe, KS Tiley, S Longet, C Tonry, C Roarty, C Watson, ... Iscience 26 (12), 2023 | | 2023 |
| EE746 Cost-Effectiveness of Vaccination Strategies to Control Future Mpox Outbreaks in England XS Zhang, S Niyomsri, S Mandal, H Mohammed, M Mindlin, B Dugbazah, ... Value in Health 26 (12), S198, 2023 | | 2023 |
| Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with … FCM Kirsebom, K Harman, RJ Lunt, N Andrews, N Groves, NA Aziz, ... The Lancet Regional Health–Europe 35, 2023 | 8 | 2023 |
| Paediatric acute hepatitis of unknown aetiology: a national investigation and adenoviraemia case-control study in the UK S Mandal, R Simmons, G Ireland, A Charlett, M Desai, L Coughlan, ... The Lancet Child & Adolescent Health 7 (11), 786-796, 2023 | 6 | 2023 |
| Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfection AC Dowell, G Tut, J Begum, R Bruton, C Bentley, M Butler, G Uwenedi, ... Journal of Infection 87 (5), 403-412, 2023 | 3 | 2023 |
| Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA. 1 boosters against COVID-19 hospitalisation in England: a test-negative case … FCM Kirsebom, N Andrews, J Stowe, M Ramsay, JL Bernal The Lancet Infectious Diseases 23 (11), 1235-1243, 2023 | 28 | 2023 |
| National public health response to an outbreak of toxigenic Corynebacterium diphtheriae among asylum seekers in England, 2022: a descriptive epidemiological study S O'Boyle, HE Barton, JC D'Aeth, R Cordery, NK Fry, D Litt, R Southgate, ... The Lancet Public Health 8 (10), e766-e775, 2023 | 5 | 2023 |
| COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study HJ Whitaker, RSM Tsang, R Byford, C Aspden, E Button, PS Pillai, ... Journal of Infection 87 (4), 315-327, 2023 | 6 | 2023 |
| Trends in invasive Haemophilus influenzae serotype a disease in England from 2008–09 to 2021–22: a prospective national surveillance study M Bertran, JC D'Aeth, E Hani, Z Amin-Chowdhury, NK Fry, ME Ramsay, ... The Lancet Infectious Diseases 23 (10), 1197-1206, 2023 | 7 | 2023 |
| Effectiveness of the adjuvanted Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA. 4-5) bivalent vaccines against hospitalisation amongst adults … FCM Kirsebom, N Andrews, J Stowe, G Dabrera, M Ramsay, JL Bernal medRxiv, 2023.09. 28.23296290, 2023 | 5 | 2023 |
| High attack rate in a large care home outbreak of SARS-CoV-2 BA. 2.86, East of England, August 2023 L Reeve, E Tessier, A Trindall, NIBA Aziz, N Andrews, M Futschik, ... Eurosurveillance 28 (39), 2300489, 2023 | 13 | 2023 |
